LLY — Put-Selling Research

by ThetaLoop Research
← Back to search
Last close: 2026-04-02
Eli Lilly and Company
Healthcare · $935.58
5.2
/10
Neutral
How this score works →
Regime
Bullish
vs SMA200
SMA200 Distance
+4.2%
Above trend
Volatility
Low
Thin premiums
Momentum
Accelerating
Price direction
About Eli Lilly and Company
Eli Lilly manufactures GLP-1 drugs Mounjaro and Zepbound for diabetes and obesity, driving explosive revenue growth. Beta ~0.50, tiny ~0.7% yield — trades like a growth stock with a high nominal share price. Wide premium swings around FDA events and earnings; attractive but risky for put sellers.
Pharmaceuticals — Major
Market Cap
$837.4B
P/E Ratio
40.8
Dividend
67.00%
Beta
0.50
52-Week Range Current: $935.58
$623.78 $1133.95
Earnings
2026-04-30
25 days away
📊 View Full Research Track Record (All Wins AND Losses)
These free tools show market conditions and individual scores.
Our daily research goes deeper — covering option-specific data points, strike analysis, and risk metrics delivered via Telegram.
EXPLORE OUR RESEARCH — 14 DAYS FREE